EpCAM tumor specificity and proteoform patterns in urothelial cancer
Journal of Cancer Research and Clinical Oncology · 2023
DOI: 10.1007/s00432-023-04809-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cancer Research and Clinical Oncology, 2023. Verfasst von Franz F Dressler und 3 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pathology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin I…. Hauptthemen laut MEDLINE: Carcinoma, Transitional Cell, Urinary Bladder Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Else Kröner-Fresenius-Stiftung, Charité - Universitätsmedizin Berlin.
Abstract (Originalsprache)
Background
The role of the epithelial cell adhesion molecule (EpCAM) in cancer is still unclear. EpCAM cleavage through regulated intramembrane proteolysis results in fragments which interact with both oncogenic and tumor suppressive pathways. Additionally, the EpCAM molecule itself is used as a descriptive therapeutic target in urothelial cancer (UC), while data on its actual tumor specificity remain limited.
Methods
Samples from diagnostic formalin-fixed paraffin-embedded (FFPE) UC tissue and fresh-frozen UC cells were immunoblotted and used for qualitative characterization of five different EpCAM fragments. These expression patterns were quantified across a cohort of 76 samples with 52 UC and 24 normal urothelial samples. Cell viability effects of the extracellular EpEX fragment were assessed in the UC cell lines T24 and HT1376.
Results
The proteolytic EpCAM fragments could be identified in clinical FFPE tissue specimens too. Neither overall nor fragment-specific EpCAM expression showed relevant tumor specificity. EpEX and its deglycosylated variant showed an inverse relationship across healthy and tumor tissue with a decrease of deglycosylated EpEX in tumors. However, extracellular EpEX did not show a relevant effect in vitro.
Conclusions
EpCAM should not be regarded as tumor-specific in UC without patient-specific predictive testing. EpCAM fragment patterns indicate cancer-specific changes and could be involved in its complex tumor-biological role.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Pathology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Charitéplatz 1, 10117, Berlin, Germany. franz-frie…
- Institute of Pathology, University Medical Center Schleswig-Holstein, Campus Lübeck, Lübeck, Germany. franz-friedrich.dressler@charite.de.
- Institute of Pathology, University Medical Center Schleswig-Holstein, Campus Lübeck, Lübeck, Germany.
- Department of Urology, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany.
- Institute of Pathology, Research Center Borstel, Leibniz Lung Center, Borstel, Germany.
- Institute of Pathology and Hematopathology, Hamburg, Germany.
Förderung
- Else Kröner-Fresenius-Stiftung
- Charité - Universitätsmedizin Berlin
Zitieren
APA
Dressler, F. F., Hinrichs, S., Roesch, M. C., & Perner, S. (2023). EpCAM tumor specificity and proteoform patterns in urothelial cancer. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-023-04809-9
Vancouver
Dressler FF, Hinrichs S, Roesch MC, Perner S. EpCAM tumor specificity and proteoform patterns in urothelial cancer. Journal of Cancer Research and Clinical Oncology. 2023. doi:10.1007/s00432-023-04809-9
BibTeX
@article{Dressler2023,
author = {Dressler, Franz F and Hinrichs, Sofie and Roesch, Marie C and Perner, Sven},
title = {EpCAM tumor specificity and proteoform patterns in urothelial cancer},
journal = {Journal of Cancer Research and Clinical Oncology},
year = {2023},
doi = {10.1007/s00432-023-04809-9}
}
EUVIMED